beta blocker: be contraindicated in heart failure

from Quasimodo
0.2 0.4 0.6 0.8 Plausible Typical Remarkable Salient

Related concepts

Parents agent
Weight: 0.65
, high blood pressure
Weight: 0.63
, heart disease
Weight: 0.63
, vasodilator
Weight: 0.62
Siblings atenolol
Weight: 0.53
, lung cancer
Weight: 0.33
, cystic fibrosis
Weight: 0.33
, agonist
Weight: 0.32
, blood clot
Weight: 0.32

Related properties

Property Similarity
be contraindicated in heart failure 1.00
be contraindicated in decompensated heart failure 0.98
be contraindicated in acute heart failure 0.97
be contraindicated in heart block 0.95
be contraindicated in in raynaud 0.93
be contraindicated in copd 0.93
be contraindicated in myasthenia gravis 0.92
be contraindicated in patients 0.92
be contraindicated in disease 0.92
be contraindicated in shock 0.92

Priors about this statement

Cues

0.2 0.4 0.6 0.8 Joint Necessity Sufficiency Implication Entailment Contradiction Entropy

Evidence

0.2 0.4 0.6 0.8 Plausible Typical Remarkable Salient

Clauses

Remarkability exclusitivity between siblings

0.09
Rule weight: 0.13
Evidence weight: 0.65
Similarity weight: 1.00
Evidence: 0.68
¬ Remarkable(beta blocker, be contraindicated in heart failure)
Evidence: 0.52
¬ Remarkable(atenolol, be contraindicated in heart failure)

Remarkability from sibling implausibility

0.55
Rule weight: 0.60
Evidence weight: 0.91
Similarity weight: 1.00
Evidence: 0.76
Plausible(beta blocker, be contraindicated in heart failure)
Evidence: 0.52
Remarkable(atenolol, be contraindicated in heart failure)
Evidence: 0.79
¬ Plausible(atenolol, be contraindicated in heart failure)

Salient implies Plausible

0.22
Rule weight: 0.28
Evidence weight: 0.80
Similarity weight: 1.00
Evidence: 0.76
Plausible(beta blocker, be contraindicated in heart failure)
Evidence: 0.86
¬ Salient(beta blocker, be contraindicated in heart failure)

Similarity expansion

0.74
Rule weight: 0.85
Evidence weight: 0.89
Similarity weight: 0.98
Evidence: 0.86
Salient(beta blocker, be contraindicated in heart failure)
Evidence: 0.79
¬ Salient(beta blocker, be contraindicated in decompensated heart failure)
0.73
Rule weight: 0.85
Evidence weight: 0.88
Similarity weight: 0.97
Evidence: 0.86
Salient(beta blocker, be contraindicated in heart failure)
Evidence: 0.83
¬ Salient(beta blocker, be contraindicated in acute heart failure)
0.72
Rule weight: 0.85
Evidence weight: 0.86
Similarity weight: 0.98
Evidence: 0.79
Typical(beta blocker, be contraindicated in heart failure)
Evidence: 0.66
¬ Typical(beta blocker, be contraindicated in decompensated heart failure)
0.72
Rule weight: 0.85
Evidence weight: 0.91
Similarity weight: 0.93
Evidence: 0.79
Typical(beta blocker, be contraindicated in heart failure)
Evidence: 0.44
¬ Typical(beta blocker, be contraindicated in in raynaud)
0.72
Rule weight: 0.85
Evidence weight: 0.91
Similarity weight: 0.93
Evidence: 0.86
Salient(beta blocker, be contraindicated in heart failure)
Evidence: 0.66
¬ Salient(beta blocker, be contraindicated in in raynaud)
0.72
Rule weight: 0.85
Evidence weight: 0.91
Similarity weight: 0.93
Evidence: 0.86
Salient(beta blocker, be contraindicated in heart failure)
Evidence: 0.66
¬ Salient(beta blocker, be contraindicated in copd)
0.72
Rule weight: 0.85
Evidence weight: 0.92
Similarity weight: 0.92
Evidence: 0.79
Typical(beta blocker, be contraindicated in heart failure)
Evidence: 0.40
¬ Typical(beta blocker, be contraindicated in myasthenia gravis)
0.71
Rule weight: 0.85
Evidence weight: 0.90
Similarity weight: 0.93
Evidence: 0.79
Typical(beta blocker, be contraindicated in heart failure)
Evidence: 0.50
¬ Typical(beta blocker, be contraindicated in copd)
0.71
Rule weight: 0.85
Evidence weight: 0.84
Similarity weight: 0.98
Evidence: 0.76
Plausible(beta blocker, be contraindicated in heart failure)
Evidence: 0.67
¬ Plausible(beta blocker, be contraindicated in decompensated heart failure)
0.71
Rule weight: 0.85
Evidence weight: 0.87
Similarity weight: 0.95
Evidence: 0.86
Salient(beta blocker, be contraindicated in heart failure)
Evidence: 0.89
¬ Salient(beta blocker, be contraindicated in heart block)
0.70
Rule weight: 0.85
Evidence weight: 0.90
Similarity weight: 0.92
Evidence: 0.86
Salient(beta blocker, be contraindicated in heart failure)
Evidence: 0.72
¬ Salient(beta blocker, be contraindicated in myasthenia gravis)
0.70
Rule weight: 0.85
Evidence weight: 0.88
Similarity weight: 0.93
Evidence: 0.76
Plausible(beta blocker, be contraindicated in heart failure)
Evidence: 0.50
¬ Plausible(beta blocker, be contraindicated in in raynaud)
0.70
Rule weight: 0.85
Evidence weight: 0.84
Similarity weight: 0.97
Evidence: 0.79
Typical(beta blocker, be contraindicated in heart failure)
Evidence: 0.75
¬ Typical(beta blocker, be contraindicated in acute heart failure)
0.70
Rule weight: 0.85
Evidence weight: 0.88
Similarity weight: 0.93
Evidence: 0.76
Plausible(beta blocker, be contraindicated in heart failure)
Evidence: 0.53
¬ Plausible(beta blocker, be contraindicated in copd)
0.69
Rule weight: 0.85
Evidence weight: 0.88
Similarity weight: 0.92
Evidence: 0.76
Plausible(beta blocker, be contraindicated in heart failure)
Evidence: 0.51
¬ Plausible(beta blocker, be contraindicated in myasthenia gravis)
0.69
Rule weight: 0.85
Evidence weight: 0.83
Similarity weight: 0.97
Evidence: 0.76
Plausible(beta blocker, be contraindicated in heart failure)
Evidence: 0.73
¬ Plausible(beta blocker, be contraindicated in acute heart failure)
0.67
Rule weight: 0.85
Evidence weight: 0.83
Similarity weight: 0.95
Evidence: 0.79
Typical(beta blocker, be contraindicated in heart failure)
Evidence: 0.82
¬ Typical(beta blocker, be contraindicated in heart block)
0.66
Rule weight: 0.85
Evidence weight: 0.81
Similarity weight: 0.95
Evidence: 0.76
Plausible(beta blocker, be contraindicated in heart failure)
Evidence: 0.80
¬ Plausible(beta blocker, be contraindicated in heart block)
0.65
Rule weight: 0.85
Evidence weight: 0.78
Similarity weight: 0.97
Evidence: 0.68
Remarkable(beta blocker, be contraindicated in heart failure)
Evidence: 0.69
¬ Remarkable(beta blocker, be contraindicated in acute heart failure)
0.64
Rule weight: 0.85
Evidence weight: 0.77
Similarity weight: 0.98
Evidence: 0.68
Remarkable(beta blocker, be contraindicated in heart failure)
Evidence: 0.74
¬ Remarkable(beta blocker, be contraindicated in decompensated heart failure)
0.63
Rule weight: 0.85
Evidence weight: 0.78
Similarity weight: 0.95
Evidence: 0.68
Remarkable(beta blocker, be contraindicated in heart failure)
Evidence: 0.70
¬ Remarkable(beta blocker, be contraindicated in heart block)
0.61
Rule weight: 0.85
Evidence weight: 0.76
Similarity weight: 0.93
Evidence: 0.68
Remarkable(beta blocker, be contraindicated in heart failure)
Evidence: 0.74
¬ Remarkable(beta blocker, be contraindicated in copd)
0.60
Rule weight: 0.85
Evidence weight: 0.75
Similarity weight: 0.93
Evidence: 0.68
Remarkable(beta blocker, be contraindicated in heart failure)
Evidence: 0.79
¬ Remarkable(beta blocker, be contraindicated in in raynaud)
0.57
Rule weight: 0.85
Evidence weight: 0.73
Similarity weight: 0.92
Evidence: 0.68
Remarkable(beta blocker, be contraindicated in heart failure)
Evidence: 0.86
¬ Remarkable(beta blocker, be contraindicated in myasthenia gravis)

Typical and Remarkable implies Salient

0.13
Rule weight: 0.14
Evidence weight: 0.92
Similarity weight: 1.00
Evidence: 0.86
Salient(beta blocker, be contraindicated in heart failure)
Evidence: 0.79
¬ Typical(beta blocker, be contraindicated in heart failure)
Evidence: 0.68
¬ Remarkable(beta blocker, be contraindicated in heart failure)

Typical implies Plausible

0.39
Rule weight: 0.48
Evidence weight: 0.81
Similarity weight: 1.00
Evidence: 0.76
Plausible(beta blocker, be contraindicated in heart failure)
Evidence: 0.79
¬ Typical(beta blocker, be contraindicated in heart failure)

Typicality and Rermarkability incompatibility between siblings

0.06
Rule weight: 0.14
Evidence weight: 0.41
Similarity weight: 1.00
Evidence: 0.68
¬ Remarkable(beta blocker, be contraindicated in heart failure)
Evidence: 0.86
¬ Typical(atenolol, be contraindicated in heart failure)